A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)

Sponsor
Grit Biotechnology
Study ID
NCT07253259
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • GT729 Injection — BIOLOGICAL
    GT729 Injection

Study Details

The goal of this clinical study is to evaluate the safety and efficacy of GT729 universal cell injection in the treatment of refractory or relapsed chronic graft-versus-host disease (cGVHD).

Key Dates

Start date
Dec 18, 2025
Status verified
Apr 2026
Primary completion
Nov 30, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: GT729 Injection treatment group
    GT729 Injection

Primary Outcome Measure

Proportion of participants experiencing dose limiting toxicity [ Time Frame: 28 days ]

Central Contacts

Related Studies